Abstract: Direct Image Lookup (DIL) metadata is used to perform differential operation for snapshots and linked targets. Each snapshot contains metadata to store “images” to perform direct lookup of user data for any part of any snapshot in the system. Metadata pages of DIL image data represent sets of tracks of data. Metadata pages of subsequent snapshots for the same sets of tracks are compared, and where there are no changes to a given metadata page for a given set of tracks between subsequent snapshot copies, the differential process is not run on the tracks associated with the metadata page. If a given metadata page associated with a set of tracks has changed between subsequent snapshots, the differential process is used to identify which tracks in the subsequent snapshot contain different data than the corresponding tracks of the previous snapshot. Similar differential processing also is implemented for relinked target devices.

Abstract: The present invention relates to a liquid, propellant-free pharmaceutical preparation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) an active substance selected from umeclidinium bromide and vilanterol trifenatate and combinations thereof; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; and (d) a pharmacologically acceptable preservative, and optionally includes a pharmacologically acceptable stabilizer, a pharmacologically acceptable co-solvent, or other pharmacologically acceptable additives.

Abstract: The present application provides a display panel and a driving method of the display panel. The display panel includes an output circuit board having multiple output terminals. The output terminal includes at least two output channels, one of which is electrically connected to one of data lines. At a first moment, a first portion of subpixels in an i-th row receive data signals input from the corresponding data lines. At a second time, a second portion of the sub-pixels in the i-th row excluding the first portion receive data signals input from the corresponding data lines.

Abstract: The invention is directed to an inhalation atomizer comprising a counter and a blocking function. Counter rotates each time the atomizer is actuated. The blocking function includes a first protrusion on the counter and a second protrusion on a lower unit of the atomizer. Once the predetermined number of actuations has been achieved, the first protrusion encounters the second protrusion and prevents further rotation of the counter so that the atomizer is blocked from further use.

Abstract: The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer.

Abstract: The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) active substances selected from umeclidinium bromide and vilanterol trifenatate; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative; and (e) a pharmacologically acceptable stabilizer; and optionally includes other pharmacologically acceptable additives.

Abstract: The present invention is directed to a liposomal formulation having a lipid ingredient encapsulating fluticasone furoate, and a method for preparing the liposomal formulation. The liposome formulation comprises a lipid and a sterol. The method of preparing the liposomes comprises the steps of (1) mixing fluticasone furoate with lipid ingredients comprising a lipid and a sterol, (2) injecting the mixture into normal saline solution, and (3) ultrafiltering and concentrating the resulting solution. This preparation method can produce a liposome formulation having desirable properties and compositions, for example, the ratio of the lipid ingredient, the drug to lipid ratio, and the pH value, which is suitable for nebulization inhalation.

Abstract: The present invention relates to stable formulations of a solution of nanoantibody drug that is suitable for inhalation and a method of treating acquired thrombotic thrombocytopenic purpura by administering the drug by inhalation using a soft mist inhaler or nebulizer. The pharmaceutical formulation for inhalation comprises caplacizumab.

Abstract: The present invention is directed to a liquid pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation with an inhaler. The propellant-free pharmaceutical formulation comprises: (a) active substances selected from budesonide and olodaterol; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative, and (e) a pharmacologically acceptable stabilizer.

Abstract: A liquid crystal display device includes a display panel, a printed circuit board assembly, a chip carrier film structure connected to the display panel and the printed circuit board assembly, a frame, and an electrostatic discharge structure. The electrostatic discharge structure includes a grounding structure disposed on the printed circuit board assembly. A grounding element is electrically connected to a side of the grounding structure of the printed circuit board assembly. A peripheral electrostatic discharge trace is disposed between the frame and the display panel and is connected to the grounding element, and includes a first guiding portion. A voltage regulating element is electrically connected between the grounding structure of the printed circuit board assembly and the first guiding portion of the peripheral electrostatic discharge trace.

Abstract: The disclosure provides a polarizer and a display panel. The polarizer is disposed in the display panel and includes a body layer and a touch control layer disposed on the body layer. The touch control layer includes a plurality of touch sensors. An area of the touch control layer is greater than or equal to an area of the display area of the display panel, and the touch control layer is electrically connected to the touch driver circuit by a wire. In the display panel, a bonding area of the touch control layer and touch units are disposed on a same layer, thereby reducing a non-display area.

Abstract: The present invention relates to a pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation with an inhaler. The propellant-free pharmaceutical formulation comprises: batefenterol or a pharmaceutically acceptable salt thereof, fluticasone furoate, and a pH adjusting agent.

Abstract: The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer.

Abstract: The present invention discloses a touch control panel, including: an upper polarizer, a color filter glass, a TFT glass, a lower polarizer, a PCB board, a flexible circuit board, a touch control driver, and a first touch control layer and a second touch control layer formed on both sides of the upper polarizer. The first touch control layer includes a plurality of first touch control electrodes; the second touch control layer includes a plurality of second touch control electrodes; and the plurality of first touch control electrodes and the plurality of second touch control electrodes are crisscrossed.

Abstract: This invention relates to pharmaceutical formulations of therapeutic monoclonal antibody drugs and pharmaceutically acceptable excipients and a novel therapeutic strategy for the treatment of lung cancers including metastatic NSCLC by administration of such formulations using a soft mist inhaler and/or nebulizer. The pharmaceutical formulations comprise (a) a therapeutic monoclonal antibody selected from the group consisting of pembrolizumab, atezolizumab, nivolumab, durvalumab, and bevacizumab, (b) water, and (c) a buffer. The pharmaceutical formulations are delivered locally to the lungs by inhalation for treatment of cancer.

Abstract: The present invention relates to a liquid pharmaceutical formulation and a method for administering a pharmaceutical formulation by nebulizing the pharmaceutical formulation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) budesonide, olodaterol and tiotropium bromide; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative, (e) and a pharmacologically acceptable stabilizer, optionally including other pharmacologically acceptable additives.

Abstract: The present invention relates to a liquid pharmaceutical formulation and a method for administering the pharmaceutical formulation by nebulizing the pharmaceutical formulation with an inhaler. The propellant-free pharmaceutical formulation comprises: (a) an active substance selected from the group consisting of alanine metabolite, nucleoside monophosphate, nucleoside triphosphate, and GS-441524; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative; and (e) a pharmacologically acceptable stabilizer.

Abstract: The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) glycopyrrolate and indacaterol maleate; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative, (e) a pharmacologically acceptable stabilizer.

Abstract: The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) active substances selected from umeclidinium bromide and vilanterol trifenatate; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative; and (e) a pharmacologically acceptable stabilizer; and optionally includes other pharmacologically acceptable additives.

Abstract: The disclosure provides a chip on film (COF) and a display device. The COF includes a substrate, a driver chip, and a heat dissipation component. A plurality of signal terminals and a plurality of heat dissipation terminals are formed on the substrate. The driver chip includes a plurality of signal pins and a plurality of heat dissipation pins. The signal pins are connected to the signal terminals, and the heat dissipation pins are connected to the heat dissipation terminals. By disposing the heat dissipation pins on the driver chip, heat generated from the driver chip may be dissipated. Therefore, a large heat dissipation area of the driver chip may be realized, which solves a problem that temperatures of conventional COFs are too high.